Keith G. Mansfield

Keith G. Mansfield

Auto-generated profile, based on publicly available information

Keith G. Mansfield

Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2017 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DODonald M. O’rourke
Donald M. O’rourke
MNMacLean Pancoast Nasrallah
MacLean Pancoast Nasrallah
ADArati Desai
Arati Desai
Jan Joseph MelenhorstJan Joseph Melenhorst
Jan Joseph Melenhorst
KMKeith Mansfield
Keith Mansfield
MMMarcela V. Maus
Marcela V. Maus
A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.

12 September 2017 in Science Signaling
Verified
Journal Article
Closed access
PDF file
TSThomas Suply
Thomas Suply
SHSébastien Hannedouche
Sébastien Hannedouche
NCNathalie Carte
Nathalie Carte
JLJianping Li
Jianping Li
BGBianka Grosshans
Bianka Grosshans
FBFrédéric Bassilana
Frédéric Bassilana
GPR15 is an orphan G protein–coupled receptor (GPCR) that is found in lymphocytes. It functions as a co-receptor of simian immunodeficiency virus and HIV-2 and plays a role in the trafficking of T cells to the lamina propria in the colon and to the skin. We describe the purification from porcine colonic tissue extracts of an agonistic ligand for GPR15 and its functional characterization. In humans, this ligand, which we named GPR15L, is encoded by the gene C10ORF99 and has some features similar to the CC family of chemokines. GPR15L was found in some human and mouse epithelia exposed to the environment, such as the colon and skin. In humans, GPR15L was also abundant in the cervix. In skin, GPR15L was readily detected after immunologic challenge and in human disease, for example, in psoriatic lesions. Allotransplantation of skin from Gpr15l-deficient mice onto wild-type mice resulted in substantial graft protection, suggesting nonredundant roles for GPR15 and GPR15L in the generation of effector T cell responses. Together, these data identify a receptor-ligand pair that is required for immune homeostasis at epithelia and whose modulation may represent an alternative approach to treating conditions affecting the skin such as psoriasis.

21 November 2022 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
AGAlfred L. Garfall
Alfred L. Garfall
ACAdam Cohen
Adam Cohen
SSSandra P. Susanibar-Adaniya
Sandra P. Susanibar-Adaniya
WHWei-Ting Hwang
Wei-Ting Hwang
DVDan T. Vogl
Dan T. Vogl
ESEdward A. Stadtmauer
Edward A. Stadtmauer
We conducted a phase I clinical trial of anti-BCMA chimeric antigen receptor T cells (CART-BCMA) with or without anti-CD19 CAR T cells (huCART19) in multiple myeloma (MM) patients responding to third- or later-line therapy (phase A, N = 10) or high-risk patients responding to first-line therapy (phase B, N = 20), followed by early lenalidomide or pomalidomide maintenance. We observed no high-grade cytokine release syndrome (CRS) and only one instance of low-grade neurologic toxicity. Among 15 subjects with measurable disease, 10 exhibited partial response (PR) or better; among 26 subjects responding to prior therapy, 9 improved their response category and 4 converted to minimal residual disease (MRD)–negative complete response/stringent complete response. Early maintenance therapy was safe, feasible, and coincided in some patients with CAR T-cell reexpansion and late-onset, durable clinical response. Outcomes with CART-BCMA + huCART19 were similar to CART-BCMA alone. Collectively, our results demonstrate favorable safety, pharmacokinetics, and antimyeloma activity of dual-target CAR T-cell therapy in early lines of MM treatment. Significance: CAR T cells in early lines of MM therapy could be safer and more effective than in the advanced setting, where prior studies have focused. We evaluated the safety, pharmacokinetics, and efficacy of CAR T cells in patients with low disease burden, responding to current therapy, combined with standard maintenance therapy. This article is highlighted in the In This Issue feature, p. 101

3 June 2022 in Toxicologic Pathology
Verified
Journal Article
Open access
EMEmily K. Meseck
Emily K. Meseck
GGGhiabe Guibinga
Ghiabe Guibinga
SWStephen Wang
Stephen Wang
CMCameron McElroy
Cameron McElroy
EHEloise Hudry
Eloise Hudry
KMKeith Mansfield
Keith Mansfield
Biodistribution of self-complementary adeno-associated virus-9 (scAAV9)–chicken β-actin promoter–green fluorescent protein (GFP) was assessed in juvenile cynomolgus macaques infused intrathecally via lumbar puncture or the intracisterna magna (1.0×1013 or 3.0×1013 vg/animal), with necropsy 28 days later. Our results characterized central nervous system biodistribution compared with systemic organs/tissues by droplet digital polymerase chain reaction for DNA and in situ hybridization. Green fluorescent protein expression was characterized by Meso Scale Discovery electrochemiluminescence immunosorbent assay and immunohistochemistry (IHC). Biodistribution was widespread but variable, with vector DNA and GFP expression greatest in the spinal cord, dorsal root ganglia (DRG), and certain systemic tissues (e.g., liver), with low concentrations in many brain regions despite direct cerebrospinal fluid administration. Transduction and expression were observed primarily in perivascular astrocytes in the brain, with a paucity in neurons. Greater GFP expression was observed in hepatocytes, striated myocytes, cardiomyocytes, spinal cord lower motor neurons, and DRG sensory neurons by IHC. These results should be considered when evaluating scAAV9-based intrathecal delivery with the current expression cassette as a modality for neurologic diseases that require widespread brain neuronal expression. This capsid/expression cassette combination may be better suited for diseases that express a secreted protein and/or do not require widespread brain neuronal transduction.

21 March 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JPJean Publicover
Jean Publicover
AGAnuj Gaggar
Anuj Gaggar
JJJillian M. Jespersen
Jillian M. Jespersen
UHUgur Halac
Ugur Halac
AJAudra J. Johnson
Audra J. Johnson
JBJody L. Baron
Jody L. Baron
Depending on age of acquisition, hepatitis B virus (HBV) can induce a cell-mediated immune response that results in either cure or progressive liver injury. In adult-acquired infection, HBV antigens are usually cleared, whereas in infancy-acquired infection, they persist. Individuals infected during infancy therefore represent the majority of patients chronically infected with HBV (CHB). A therapy that can promote viral antigen clearance in most CHB patients has not been developed and would represent a major health care advance and cost mitigator. Using an age-dependent mouse model of HBV clearance and persistence in conjunction with human blood and liver tissue, we studied mechanisms of viral clearance to identify new therapeutic targets. We demonstrate that age-dependent expression of the costimulatory molecule OX40 ligand (OX40L) by hepatic innate immune cells is pivotal in determining HBV immunity, and that treatment with OX40 agonists leads to improved HBV antigen clearance in young mice, as well as increased strength of T cell responses in young mice and adult mice that were exposed to HBV when they were young and developed a CHB serological profile. Similarly, in humans, we show that hepatic OX40L transcript expression is age-dependent and that increased OX40 expression on peripheral CD4+ T cells in adults is associated with HBV clearance. These findings provide new mechanistic understanding of the immune pathways and cells necessary for HBV immunity and identify potential therapeutic targets for resolving CHB.

1 September 2000 in Veterinary Pathology
Verified
Journal Article
Open access
TYT. Yanai
T. Yanai
LCL. V. Chalifoux
L. V. Chalifoux
KMK. G. Mansfield
K. G. Mansfield
ALA. A. Lackner
A. A. Lackner
MSM. A. Simon
M. A. Simon
Cryptosporidiosis is a common opportunistic infection in the gastrointestinal tract of human and nonhuman primates with AIDS. Pulmonary infection associated with Cryptosporidium spp. has not been previously reported in monkeys. Two macaques experimentally infected with simian immunodeficiency virus (SIV) had lesions containing cryptosporidial organisms involving the trachea, lungs, bile ducts, pancreas, and intestine. The pulmonary sections revealed moderate to severe bronchopneumonia associated with cryptosporidiosis. Numerous 2-4 μm oval Cryptosporidium spp. organisms were present in the cytoplasm of alveolar macrophages, multinucleated giant cells, and intestinal epithelial cells. Giant cells were positive for SIV by in situ hybridization. These are the first reported cases of cryptosporidiosis with involvement of pulmonary parenchyma in SIV-infected macaques.